Read by QxMD icon Read

recurrent risk factors hepatocellular carcinoma

Weiwei Yan, Zhenyu Zhu, Fei Pan, Ang Huang, Guang-Hai Dai
Background: To explore new biomarkers for indicating the recurrence and prognosis in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients after tumor resection, we investigated the expression and prognostic value of c-kit(CD117) in HBV-related HCC. Materials and methods: Immunohistochemistry was used to estimate the expression of c-kit(CD117) and CD34 in the liver cancer tissues. The correlations between the expression of these biomarkers and the clinicopathologic characteristics were analyzed...
2018: OncoTargets and Therapy
Yukio Tokumitsu, Kazuhiko Sakamoto, Yoshihiro Tokuhisa, Hiroto Matsui, Satoshi Matsukuma, Yoshinari Maeda, Koichiro Sakata, Hiroshi Wada, Hidetoshi Eguchi, Hiroyuki Ogihara, Yusuke Fujita, Yoshihiko Hamamoto, Norio Iizuka, Tomio Ueno, Hiroaki Nagano
We previously reported the effectiveness of the product of tumor number and size (NxS factor) for the prognosis of hepatocellular carcinoma (HCC) in patients following hepatectomy. The present study aimed to propose a new score based on the NxS factor to predict HCC recurrence following hepatectomy. A total of 406 patients who underwent hepatectomy for HCC at Osaka University Graduate School of Medicine were retrospectively analyzed to develop the new score. Among clinicopathological factors, including the NxS factor, the marker subset that achieved the best performance for prediction of early recurrence was assessed, and a prognostic model for HCC recurrence after curative hepatectomy (REACH) was developed...
April 2018: Oncology Letters
Jian Liu, Qian Zhu, Yun Li, Guo-Liang Qiao, Chang Xu, De-Liang Guo, Jie Tang, Rui Duan
BACKGROUND: We aimed to identify the independent predictive factors of microvascular invasion (MVI) for curative resection of HCC and to investigate the impacts of MVI and HBeAg on long-term recurrence and survival after resection. METHODS: The clinicopathological parameters of 237 patients with HCC with MVI who underwent hepatic resection from April 2005 to November 2010 were investigated. Clinical features and factors associated with the clinical outcomes of 386 patients with HCC without MVI were used for comparison...
March 15, 2018: Clinics and Research in Hepatology and Gastroenterology
Ivan Schietroma, Giuseppe Corano Scheri, Claudia Pinacchio, Maura Statzu, Arnolfo Petruzziello, Vincenzo Vullo
Introduction: Globally, between 64 and 103 million people are chronically infected with Hepatitis C virus (HCV), with more than 4.6 million people in the United States and is associated with more than 15.000 deaths annually. Chronic infection can result in cirrhosis and hepatocellular carcinoma. Explanation: Epidemiological studies have indicated that persistent infection with hepatitis C virus (HCV) is a major risk for the development of hepatocellular carcinoma (HCC), mainly through chronic inflammation, cell deaths, and proliferation...
2018: Open Virology Journal
Xiaomeng Dai, Guoliang Pi, Sheng-Li Yang, George G Chen, Li-Ping Liu, Han-Hua Dong
OBJECTIVE: To investigate the correlation between the expression of PD-L1 and HIF-1α in hepatocellular carcinoma (HCC) tissue and further analyze the association with clinical parameters and the prognostic value of coexpression in HCC patients. METHODS: We assessed the expression of PD-L1 and HIF-1α by immunohistochemistry in tumor tissue from 90 HCC patients who underwent curative hepatectomy. The results were validated in an independent cohort of additional 90 HCC patients...
March 8, 2018: Translational Oncology
Gang Huang, Peng-Peng Li, Wan Yee Lau, Ze-Ya Pan, Ling-Hao Zhao, Zhen-Guang Wang, Meng-Chao Wang, Wei-Ping Zhou
BACKGROUND: Despite antiviral treatment has been shown to reduce hepatocellular carcinoma (HCC) recurrence after curative treatment for hepatitis B virus (HBV)-related HCC in patients with high preoperative HBV-DNA levels, it is still unclear whether antiviral therapy is useful in reducing recurrence in patients with low preoperative HBV-DNA levels. METHODS: In this randomized controlled trial, 200 patients who underwent curative resection for HCC with low baseline HBV-DNA levels were randomly assigned to receive preemptive antiviral therapy or not...
March 8, 2018: Annals of Surgery
Jong Man Kim, Nam-Joon Yi, Choon Hyuck David Kwon, Kwang-Woong Lee, Kyung-Suk Suh, Jae-Won Joh
Purpose: Although few hepatectomy patients develop unexpected early diffuse and multinodular recurrence in the remnant liver, the prognosis in such cases is often dismal. The aim of this study was to evaluate the risk factors of early disseminated multinodular hepatocellular carcinoma (HCC) recurrence within 3 months after liver resection for solitary HCC. Methods: Eighty-four patients who were diagnosed with recurrent HCC within 3 months after hepatectomy for solitary HCC were retrospectively reviewed...
March 2018: Annals of Surgical Treatment and Research
Yan Zhou, Xiaolin Xu, Jianmin Ding, Xiang Jing, Fengmei Wang, Yandong Wang, Peng Wang
Aims: Thermal ablation can evoke an immune response, which may have effects on the prognosis of patients with hepatocellular carcinoma (HCC). Our aim is to investigate the changes of circulating T-cell subsets after microwave ablation (MWA) and to explore the risk factors of tumor recurrence in patients with hepatitis B virus (HBV)-related HCC. Methods: Thirty patients with HBV-related HCC were enrolled in this study. The blood samples were collected both before and after MWA (24 h, 72 h, and 1 month after MWA)...
January 2018: Journal of Cancer Research and Therapeutics
Deborah Repullo, Marie Diaz, Stéphane Holbrechts, Maria Gomez-Galdón, Dirk Van Gestel, Ali Bohlok, Gabriel Liberale, Vincent Donckier
BACKGROUND: The development of a second primary tumor is a potential late side effect of radiotherapy. Particularly, an increased risk of secondary cancers, mostly of digestive or breast origin, has been observed in patients treated with high-dose radiotherapy for Wilms tumor (WT) in childhood. However, hepatocellular carcinoma (HCC) has been very rarely described as a potentially radiotherapy-induced tumor. We describe the case of a patient with an aggressive HCC 50 years after the treatment of a WT...
March 7, 2018: World Journal of Surgical Oncology
Zhang Zhaohui, Shen Shunli, Chen Bin, Li Shaoqiang, Hua Yunpeng, Kuang Ming, Liang Lijian, Peng Bao Gang
Purpose: The intermediate stage of HCC (BCLC B) comprises a highly heterogeneous population, and the treatment strategy is still controversial. Because of the heterogeneity, a subclassification of intermediate-stage HCCs was put forward by Bolondi et al according to the 'beyond Milan and within up-to-7'criteria and Child-Pugh score. In this study, we aim to analyze the prognosis of BCLC B stage HCC patients who received hepatic resection according to the Bolondi's subclassification. Materials and Methods: 1,103 patients diagnosed with HCC and treated with hepatic resection were enrolled in our hospital between 2006 and 2012...
February 26, 2018: Cancer Research and Treatment: Official Journal of Korean Cancer Association
Miao Wang, Lyu Zhang, Zeyang Liu, Jiamin Zhou, Qi Pan, Jia Fan, Rongyu Zang, Lu Wang
AGO1 is a major component of RNA-induced silencing complexes and plays a crucial role in solid tumors. The aim of our study was to investigate AGO1 functions in hepatocellular carcinoma (HCC). Using small interfering RNA, AGO1 functions were investigated in HCCLM3 cell lines. Cell proliferation, immigration, and invasion significantly decreased after AGO1 depletion using MTT, wound-healing, and transwell assay. The associated proteins in the epithelial-mesenchymal transition (EMT) and the activation of its signal pathways were measured using western blot...
February 27, 2018: Cell Death & Disease
Annsa C Huang, Neil Mehta, Jennifer L Dodge, Francis Y Yao, Norah A Terrault
Whether direct-acting antivirals (DAA) increase the risk of hepatocellular carcinoma (HCC) recurrence after tumor-directed therapy is controversial. We sought to determine the impact of DAA therapy on HCC recurrence after local-regional therapy (LRT) and waitlist dropout among liver transplant (LT) candidates with HCC. We performed a retrospective cohort study of 149 LT candidates with HCV and HCC at a single center from 2014-2016. Cumulative incidence of HCC recurrence post-LRT and waitlist dropout was estimated by DAA group...
February 24, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
Yukai He, Fenghua Liu, Shaofeng Mou, Qingyan Li, Sikui Wang
The aim of this study was to analyze the correlation between the quantitative parameters of contrast-enhancement ultrasound for primary hepatocellular carcinoma (HCC) and biological manifestations of tumor (Ki-67), and to explore the related risk factors of primary hepatocellular carcinoma, so as to provide the theoretical basis for the further study on contrast-enhancement ultrasound manifestations, clinical features and prognosis of HCC. The patients with HCC confirmed by operation or puncture were collected, and those with the background of liver cirrhosis and immunohistochemical staining for tumor sample sections were selected...
March 2018: Oncology Letters
Patrizia Burra, Alberto Zanetto, Giacomo Germani
Hepatocellular carcinoma is one of the main important causes of cancer-related death and its mortality is increasingly worldwide. In Europe, alcohol abuse accounts for approximately half of all liver cancer cases and it will become the leading cause of hepatocellular carcinoma in the next future with the sharp decline of chronic viral hepatitis. The pathophysiology of alcohol-induced carcinogenesis involves acetaldehyde catabolism, oxidative stress and chronic liver inflammation. Genetic background plays also a significant role and specific patterns of gene mutations in alcohol-related hepatocellular carcinoma have been characterized...
February 9, 2018: Cancers
Jian Zhou, Zheng Wang, Zhenggang Ren, Yi Chen, Jie Hu, Guo-Huan Yang, Lei Yu, Xin-Rong Yang, Ao Huang, Xin Zhang, Shao Lai Zhou, Hui-Chuan Sun, Yan Hong Wang, Ning Ling Ge, Xiao-Yu Xu, Zhaoyou Tang, Wan Yee Lau, Jia Fan, Jiping Wang
PURPOSE: The survival of patients with hepatocellular carcinoma (HCC) recurrence after curative resection are usually poor. We sought to evaluate the safety and efficacy of adjuvant transarterial chemoembolization (TACE) in HBV-related HCC patients with an intermediate (a single tumor larger than 5 cm without microvascular invasion) or high risk (a single tumor with microvascular invasion, or two or three tumors) of recurrence. EXPERIMENTAL DESIGN: In this randomized phase 3 trial, 280 eligible patients were assigned to adjuvant TACE (n=140) or no adjuvant treatment (control; n = 140) groups...
February 2, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Ah Yeong Kim, Dong Hyun Sinn, Woo Kyoung Jeong, Young Kon Kim, Tae Wook Kang, Sang Yun Ha, Chul Keun Park, Gyu Seong Choi, Jong Man Kim, Choon Hyuck David Kwon, Jae-Won Joh, Min-Ji Kim, Insuk Sohn, Sin-Ho Jung, Seung Woon Paik, Won Jae Lee
BACKGROUND AND AIMS: Hepatobiliary MRI provides additional information beyond size and number of the tumor, and may have prognostic implication. We tested whether pre-transplant radiologic features on MRI can stratify risk of tumor recurrence after liver transplantation (LT) for hepatocellular carcinoma (HCC). METHODS: A total of 100 liver transplanted patients who had preoperative gadoxetic acid-enhanced MRI, including the hepatobiliary phase (HBP), were reviewed for size, number, morphologic type (e...
February 2, 2018: Journal of Hepatology
Stacey B Prenner, Laura Kulik
PURPOSE OF REVIEW: To highlight the current data for treatment of hepatitis C virus (HCV) in patients with hepatocellular carcinoma (HCC) awaiting orthotopic liver transplant and incorporation of various factors to decide the optimal time to initiate HCV therapy. RECENT FINDINGS: Viral eradication on the waiting list has been found to lead to significant clinical improvement in approximately 20% of HCV-positive patients. However, there have been concerns raised for direct-acting antiviral (DAA) therapy in patients listed with HCC...
February 5, 2018: Current Opinion in Organ Transplantation
X Y Luo, C Y Du, X F Wei, N Jiang, M Li, R Liao
Objective: To investigate the correlation between Ishak inflammation score and the clinicopathological characteristics and recurrence of patients with hepatocellular carcinoma (HCC) after curative resection, and then set up a recurrence nomogram for HCC. Methods: A total of 326 patients with HCC after curative resection from January 2006 to December 2009 were studied retrospectively as training cohort and 110 HCC patients after surgery from January 2010 to December 2012 were used as validation cohort.Clinical follow-up data and peritumoral Ishak inflammation score in training cohort were used to set up a nomogram predicting recurrence of HCC, which was verified by validation cohort...
February 1, 2018: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
Chunlin Jiang, Baoxian Liu, Shuling Chen, Zhenwei Peng, Xiaoyan Xie, Ming Kuang
PURPOSE: To analyse the precise ablative margin (AM) after radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) and the correlation between AM and local tumour progression (LTP) with a three-dimension (3D) reconstruction technique. METHODS: From March 2011 to May 2013, 134 patients who underwent RFA for 159 primary or recurrent HCCs within Milan criteria were enrolled. Contrast-enhanced computed tomography (CECT) scans were performed 1 week before and 1 month after treatment...
February 2, 2018: International Journal of Hyperthermia
Zhen Kang, Enhua Xiao
Cluster of differentiation (CD)151, a member of tetraspanin family, is considered to be the first tetraspanin to be associated with tumor metastasis. Previous studies in vivo, in vitro and in the clinic have demonstrated that CD151 is involved in tumor progression at different levels through interaction with integrins, growth factor receptors and matrix metalloproteinases. Transcatheter arterial chemoembolization (TACE) is widely recommended for the treatment of patients with advanced hepatocellular carcinoma (HCC) worldwide...
January 2018: Oncology Letters
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"